Table 2 Retrospective studies of patients with EGFR ex20ins NSCLC treated with EGFR-TKIs and combination therapy
Treatment (reference) | N | Line | ORR (%) | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|
Erlotinib/gefitinib [25] | 25 | ≥2 | 8 | 2 | 9.5 |
Afatinib [26] | 23 | 1 | 8.7 | 2.7 | 9.2 |
Osimertinib 80 mg [27] | 6 | ≥2 | 66.7 | 6.2 | NA |
Osimertinib 80 mg [28] | 15 | ≥2 | 0 | 3.5 | 56.3 |
Osimertinib 160 mg [29] | 20 | ≥2 | 25 | 9.7 | NA |
Luminespib [30] | 29 | ≥2 | 17 | 2.9 | 12.8 |
Afatinib combined with cetuximab [31] | 4 | ≥2 | 75 | 5.4 | NA |